
Shares of drugmaker Gilead GILD.O fall 6% to $138.35 after market
Co forecasts 2026 adjusted profit to be in the range of $8.45 to $8.85 per share, the midpoint of which is below analysts' estimates of $8.74 per share — LSEG data
Forecasts 2026 sales to be about $29.6 billion to $30 billion, compared to consensus estimate of $30.2 billion
Co's Q4 results came in slightly above Wall Street estimates
Co says it trimmed its outlook for 2026 sales growth by about 2% due to a pricing agreement with the Trump administration and uncertainty about the number of people who will retain insurance coverage under Affordable Care Act plans now that some government subsidies have expired
GILD was up 32.8% in 2025